Longitudinally extensive transverse myelitis refers to florid and widespread inflammation of the spinal cord causing T2 hyperintensity on spinal magnetic resonance imaging that is seen to extend over three or more vertebral segments. Whilst rare, longitudinally extensive transverse myelitis is clinically important as it can lead to catastrophic morbidity, and a group of these patients are at risk of further attacks. Early identification and establishment of the underlying aetiology is vital in order to initiate appropriate therapy and optimize outcomes. Whilst longitudinally extensive transverse myelitis is classically associated with neuromyelitis optica, there are many other causes. These include other inflammatory aetiologies, infection, malignancy and metabolic disturbance. Some of these are readily treatable. Laboratory and radiological investigations can help to differentiate these causes. Treatment of longitudinally extensive transverse myelitis hinges on distinguishing inflammatory and non-inflammatory aetiologies and identifying patients who are at high risk of a recurrent course.
WingerchukDMLennonVAPittockSJLucchinettiCFWeinshenkerBG. Revised diagnostic criteria for neuromyelitis optica. Neurology2006; 66: 1485–1489.
2.
PawateSSriramS. Isolated longitudinal myelitis: a report of six cases. Spinal Cord2009; 47: 257–261.
3.
AlvarengaMPThulerLCNetoSPVasconcelosCCCamargoSGAlvarengaMP. The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol2010; 257: 992–998.
4.
GajofattoAMonacoSFioriniMZanussoGVedovelloMRossiF. Assessment of outcome predictors in first-episode acute myelitis: a retrospective study of 53 cases. Arch Neurol2010; 67: 724–730.
LennonVAWingerchukDMKryzerTJPittockSJLucchinettiCFFujiharaK. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet2004; 364: 2106–2112.
7.
WeinshenkerBGWingerchukDMVukusicSLinboLPittockSJLucchinettiCF. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol2006; 59: 566–569.
8.
WatersPJariusSLittletonELeiteMIJacobSGrayB. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol2008; 65: 913–919.
9.
PittockSJLennonVAde SezeJVermerschPHomburgerHAWingerchukDM. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol2008; 65: 78–83.
10.
MarignierRDe SezeJVukusicSDurand-DubiefFZephirHVermerschP. NMO-IgG and Devic’s neuromyelitis optica: a French experience. Mult Scler2008; 14: 440–445.
11.
MaganaSMPittockSJLennonVAKeeganBMWeinshenkerBGLucchinettiCF. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol2009; 66: 964–966.
12.
JariusSFranciottaDBergamaschiRWrightHLittletonEPalaceJ. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology2007; 68: 1076–1077.
13.
WandingerKPStangelMWitteTVenablesPCharlesPJariusS. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum2010; 62: 1198–1200.
14.
KahlenbergJM. Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjögren’s syndrome. Semin Arthritis Rheum2011; 40: 343–348.
15.
KimSMWatersPVincentAKimSYKimHJHongYH. Sjogren’s syndrome myelopathy: spinal cord involvement in Sjogren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler2009; 15: 1062–1068.
16.
BirnbaumJPetriMThompsonRIzbudakIKerrD. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum2009; 60: 3378–3387.
17.
EspinosaGMendizábalAMínguezSRamo-TelloCCapelladesJOlivéA. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: Clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum2010; 39: 246–256.
18.
RodriguesCECarvalhoJF. Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: Report of 4 cases and review of the literature. Semin Arthritis Rheum2011; 40: 349–357.
19.
TakechiUOkadaKUozumiTTsujiS. Longitudinally extensive spinal cord lesion in a case of Neuro-Behçet disease. Rinsho Shinkeigaku2008; 48: 48–51.
20.
Borhani HaghighiAAshjazadehN. Acute disseminated encephalomyelitis-like manifestations in a patient with neuro-Behçet disease. Neurologist2009; 15: 282–284.
Cohen-AubartFGalanaudDGrabliDHarocheJAmouraZChapelon-AbricC. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore)2010; 89: 133–140.
23.
BotJCBarkhofFPolmanCHLycklama a NijeholtGJde GrootVBergersE. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology2004; 62: 226–233.
24.
TartaglinoLMFriedmanDPFlandersAELublinFDKnoblerRLLiemM. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology1995; 195: 725–732.
25.
QiuWWuJSZhangMNMatsushitaTKiraJICarrollWM. Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database. J Neurol Neurosurg Psychiatry2010; 81: 209–212.
26.
NakamuraMMiyazawaIFujiharaKNakashimaIMisuTWatanabeS. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol2008; 255: 163–170.
27.
YanagawaKKawachiIToyoshimaYYokosekiAArakawaMHasegawaA. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology2009; 73: 1628–1637.
28.
KramplaWAboul-EneinFJecelJLangWFertlEHrubyW. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol2009; 19: 2535–2543.
29.
MatsuokaTMatsushitaTKawanoYOsoegawaMOchiHIshizuT. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain2007; 130: 1206–1223.
30.
ChongHTRamliNLeeKHKimBJUrsekarMDayanandaK. Magnetic resonance imaging of Asians with multiple sclerosis was similar to that of the West. Can J Neurol Sci2006; 33: 95–100.
31.
PittockSJLennonVAKreckeKWingerchukDMLucchinettiCFWeinshenkerBG. Brain abnormalities in neuromyelitis optica. Arch Neurol2006; 63: 390–396.
32.
Cabrera-GomezJAQuevedo-SotolongoLGonzalez-QuevedoALimaSReal-GonzalezYCristofol-CorominasM. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler2007; 13: 186–192.
33.
O’RiordanJIGallagherHLThompsonAJHowardRSKingsleyDPThompsonEJ. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry1996; 60: 382–387.
34.
Cabrera-GomezJSaiz-HinarejosAGrausFGonzalez-QuevedoARodriguez-RojasRQuevedo-SotolongoL. Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Mult Scler2008; 14: 248–251.
35.
PittockSJWeinshenkerBGLucchinettiCFWingerchukDMCorboyJRLennonVA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol2006; 63: 964–968.
36.
BergamaschiRToniettiSFranciottaDCandeloroETavazziEPiccoloG. Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler2004; 10: 2–4.
37.
NakamuraMNakashimaISatoSMiyazawaIFujiharaKItoyamaY. Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands. Mult Scler2007; 13: 332–335.
38.
WingerchukDMHogancampWFO’BrienPCWeinshenkerBG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology1999; 53: 1107–1114.
39.
PradhanSGuptaRKGhoshD. Parainfectious myelitis: three distinct clinico-imagiological patterns with prognostic implications. Acta Neurol Scand1997; 95: 241–247.
40.
SellnerJHemmerBMuhlauM. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun2010; 34: 371–379.
41.
Chilver-StainerLFischerUHaufMFuxCASturzeneggerM. Syphilitic myelitis: rare, nonspecific, but treatable. Neurology2009; 72: 673–675.
MeursLLabeyeDDeclercqIPieretFGilleM. Acute transverse myelitis as a main manifestation of early stage II neuroborreliosis in two patients. Eur Neurol2004; 52: 186–188.
44.
UmeharaFNoseHSaitoMFukudaMOginoMToyotaT. Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I-associated myelopathy. J Neurovirol2007; 13: 260–267.
45.
SaleemSBelalAIel-GhandourNM. Spinal cord schistosomiasis: MR imaging appearance with surgical and pathologic correlation. Am J Neuroradiol2005; 26: 1646–1654.
46.
LeeIHKimSTOhDKKimHJKimKHJeonP. MRI findings of spinal visceral larva migrans of Toxocara canis. Eur J Radiol2010; 75: 236–240.
KetelslegersIVisserINeuteboomRBoonMCatsman-BerrevoetsCHintzenR. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler2011; 17(4): 441–448.
49.
AkkadWSalemBFreemanJWHuntingtonMK. Longitudinally Extensive Transverse Myelitis Following Vaccination With Nasal Attenuated Novel Influenza A(H1N1) Vaccine. Arch Neurol2010; 67: 1018–1020.
KeeganBMPittockSJLennonVA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol2008; 63: 531–534.
53.
CrossSASalomaoDRParisiJEKryzerTJBradleyEAMinesJA. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol2003; 54: 38–50.
54.
DucrayFRoos-WeilRGarciaPYSlesariJHeinzlefOChatelainD. Devic’s syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry2007; 78: 325–327.
55.
PittockSJLucchinettiCFParisiJEBenarrochEEMokriBStephanCL. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol2005; 58: 96–107.
56.
UraiYMatsumotoKShimamuraMIkedaKTsukaguchiMDeguchiK. Paraneoplastic necrotizing myelopathy in a patient with advanced esophageal cancer: An autopsied case report. J Neurol Sci2009; 280: 113–117.
57.
AndersonDWBorsaruA. Case report: Lymphoma-related resolving paraneoplastic myelopathy with MRI correlation. Br J Radiol2008; 81: e103–E105.
58.
KurodaYMiyaharaMSakemiTMatsuiMRyuTYamaguchiM. Autopsy report of acute necrotizing opticomyelopathy associated with thyroid cancer. J Neurol Sci1993; 120: 29–32.
59.
PittockSJLennonVA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol2008; 65: 629–632.
PidcockFSKrishnanCCrawfordTOSalorioCFTrovatoMKerrDA. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology2007; 68: 1474–1480.
62.
KalraVSharmaSSahuJSankhyanNChaudhryRDhawanB. Childhood acute transverse myelitis: clinical profile, outcome, and association with antiganglioside antibodies. J Child Neurol2009; 24: 466–471.
63.
YiuEMKornbergAJRyanMMColemanLTMackayMT. Acute transverse myelitis and acute disseminated encephalomyelitis in childhood: spectrum or separate entities?J Child Neurol2009; 24: 287–296.
64.
AlperGPetropoulouKAFitzCRKimY. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler2011; 17(1): 74–80.
65.
VerheyLHBransonHMMakhijaMShroffMBanwellB. Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. Neuroradiology2010; 52: 1153–1162.
66.
McKeonALennonVALotzeTTenenbaumSNessJMRenselM. CNS aquaporin-4 autoimmunity in children. Neurology2008; 71: 93–100.
67.
KringsTGeibprasertS. Spinal dural arteriovenous fistulas. Am J Neuroradiol2009; 30: 639–648.
68.
AtkinsonJLMillerGMKraussWEMarshWRPiepgrasDGAtkinsonPP. Clinical and radiographic features of dural arteriovenous fistula, a treatable cause of myelopathy. Mayo Clin Proc2001; 76: 1120–1130.
69.
NovyJCarruzzoAMaederPBogousslavskyJ. Spinal cord ischemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. Arch Neurol2006; 63: 1113–1120.
70.
KumralEPolatFGulluogluHUzunkopruCTuncelRAlpaydinS. Spinal ischaemic stroke: clinical and radiological findings and short-term outcome. Eur J Neurol2011; 18: 232–239.
71.
LarnerAJZemanAZAllenCMAntounNM. MRI appearances in subacute combined degeneration of the spinal cord due to vitamin B12 deficiency. J Neurol Neurosurg Psychiatry1997; 62: 99–100.
72.
KumarNAhlskogJEKleinCJPortJD. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology2006; 48: 78–83.
73.
KumarNGrossJBJrAhlskogJE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology2004; 63: 33–39.
74.
DropchoEJ. Neurotoxicity of Radiation Therapy. Neurol Clin2010; 28: 217–234.
75.
KeeganMPinedaAAMcClellandRLDarbyCHRodriguezMWeinshenkerBG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology2002; 58: 143–146.
76.
LlufriuSCastilloJBlancoYRamio-TorrentaLRioJVallesM. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology2009; 73: 949–953.
77.
BonnanMValentinoROlindoSMehdaouiHSmadjaDCabreP. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler2009; 15: 487–492.
78.
WatanabeSNakashimaIMisuTMiyazawaIShigaYFujiharaK. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler2007; 13: 128–132.
79.
ElovaaraIApostolskiSvan DoornPGilhusNEHietaharjuAHonkaniemiJ. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological disease. Eur J Neurol2008; 15: 893–908.
80.
KimSHKimSMVincentAAhnSWHongYHParkKS. Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. J Neurol2010; 257: 920–925.
81.
BichuettiDBLobato de OliveiraEMOliveiraDMAmorin de SouzaNGabbaiAA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol2010; 67: 1131–1136.
82.
MandlerRNAhmedWDencoffJE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology1998; 51: 1219–1220.
83.
JacobAMatielloMWeinshenkerBGWingerchukDMLucchinettiCShusterE. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol2009; 66: 1128–1133.
84.
FalciniFTrapaniSRicciLRestiMSimoniniGde MartinoM. Sustained improvement of a girl affected with Devic’s disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford)2006; 45: 913–915.
85.
CreeBALambSMorganKChenAWaubantEGenainC. An open label study of the effects of rituximab in neuromyelitis optica. Neurology2005; 64: 1270–1272.
86.
JacobAWeinshenkerBGViolichIMcLinskeyNKruppLFoxRJ. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol2008; 65: 1443–1448.
87.
Weinstock-GuttmanBRamanathanMLincoffNNapoliSQSharmaJFeichterJ. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol2006; 63: 957–963.
88.
KimSHKimWParkMSSohnEHLiXFKimHJ. Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica. Arch Neurol2011; 68(4): 473–479.
89.
TanakaMTanakaKKomoriM. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol2009; 62: 167–170.
90.
PapeixCVidalJSde SezeJPierrot-DeseillignyCTourbahAStankoffB. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler2007; 13: 256–259.
91.
PalaceJLeiteMINairneAVincentA. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol2010; 67: 1016–1017.
92.
WarabiYMatsumotoYHayashiH. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci2007; 252: 57–61.
93.
ShimizuJHatanakaYHasegawaMIwataASugimotoIDateH. IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology2010; 75: 1423–1427.
WatanabeSMisuTMiyazawaINakashimaIShigaYFujiharaK. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler2007; 13: 968–974.
97.
SellnerJBoggildMClanetMHintzenRQIllesZMontalbanX. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol2010; 17: 1019–1032.
98.
SantosEShaunakSRenowdenSScoldingNJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry2010; 81: 241–246.
99.
PipitoneNOlivieriIPadulaAD’angeloSNigroAZuccoliG. Infliximab for the treatment of Neuro-Behcet’s disease: a case series and review of the literature. Arthritis Rheum2008; 59: 285–290.
100.
BertsiasGKIoannidisJPAringerMBollenEBombardieriSBruceIN. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis2010; 69: 2074–2082.
